Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent
Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029 — important because Dupixent faces patent expiration in 2031.
The Real Gap in All of Us Isn’t Consent, It’s Conversion
Why more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that's good news.
FDA Looks to Bring New Scientific, Consumer Voices to Advisory Committees
The FDA is recruiting to fill vacancies on its advisory committees, informally known as adcomms. While these committees have met less frequently during the Trump administration, more meetings have been scheduled since former Commissioner Marty Makary left the agency in May.
MedCity FemFwd: Opportunities in the Fertility Market
In this episode, we’re joined by Claire Love, PwC’s global health industries advisory leader. We discuss PwC’s recent report showing the opportunities in the fertility and reproductive health market.
4 Notable Health Tech Funding Announcements in September
Health tech companies made several major funding announcements in September. Here is a list of some of the biggest funding rounds.